Key statistics
As of last trade Supernus Pharmaceuticals Inc (0LB2:LSE) traded at 31.97, -9.56% below its 52-week high of 35.35, set on Aug 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 31.97 |
Low | 31.97 |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | 301.00 |
---|---|
Shares outstanding | 55.11m |
Free float | 52.33m |
P/E (TTM) | 360.24 |
Market cap | 1.75bn USD |
EPS (TTM) | 0.0883 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 16:39 BST.
More ▼
Announcements
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Announces Second Quarter 2024 Financial Results
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
- Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
- Supernus Announces First Quarter 2024 Financial Results
More ▼